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Abstract
Summary This was a longitudinal study examining the
effects of insulin use on bone mineral density loss.
Insulin use was found to be associated with greater bone
mineral density loss at the femoral neck among women
with diabetes mellitus.
Introduction Women with diabetes mellitus (DM) have
higher bone mineral density (BMD) and experience slower
BMD loss but have an increased risk of fracture. The data
regarding the effect of insulin treatment on BMD remains
conflicted. We examined the impact of insulin initiation on
BMD.
Methods We investigated the annual changes in BMD associated with the new use of insulin among women with DM in
the Study of Women’s Health Across the Nation (SWAN).
Propensity score (PS) matching, which is a statistical method
that helps balance the baseline characteristics of women who
did and did not initiate insulin, was used. Covariates with a
potential impact on bone health were included in all models.

Mixed model regression was used to test the change in BMD
between the two groups. Median follow-up time was
5.4 years.
Results The cohort consisted of 110 women, mean age,
53.6 years; 49% white and 51% black. Women using insulin
(n = 55) were similar on most relevant characteristics to the 55
not using insulin. Median diabetes duration for the user group
was 10 vs. 5.0 years for the non-user group. There was a
greater loss of BMD at the femoral neck among insulin users
(− 1.1%) vs non-users (− 0.77%) (p = 0.04). There were no
differences in BMD loss at the spine − 0.30% vs − 0.32%
(p = 0.85) or at the total hip − 0.31% vs − 0.25 (p = 0.71),
respectively.
Conclusions Women with T2DM who initiated insulin experienced a more rapid BMD loss at the femoral neck as compared to women who did use insulin.
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Diabetes mellitus (DM) and its complications contribute to
significant morbidity and mortality. Not only has DM been
shown to increase the risk for microvascular complications
(retinopathy, nephropathy, neuropathy) and macrovascular
complications (coronary heart disease, stroke, peripheral vascular disease), but it also may have affects on bone and fracture risk [1–5]. Many studies have shown that women with
DM have higher bone mineral density (BMD) than women
without DM. However, those with DM tend to have greater
bone loss and a higher rate of fracture [6–19]. Most agree that
endogenous insulin has an anabolic effect on bone [18–22].
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However, there are several mechanisms by which diabetes can
affect bone health. These include hyperglycemia,
hyperinsulinemia and insulin-like growth factor-1 (IGF-1),
antidiabetic agents, and diabetes disease severity to name a
few [19–36].
Hyperglycemia effects bone health by increasing oxidative
stress and elevating levels of advanced glycation end products
(AGE) [19, 23, 25, 26, 31, 32, 36]. Hyperinsulinemia has been
thought to increase BMD [18, 19, 21–27, 32] by some, whereas others have found it to decrease BMD [23, 28, 31, 36].
Srikanthan found that hyperinulinemia more negatively affects bone than hyperglycemia does.
The effects of medications used for T2DM likely play a
role in bone health. Numerous studies have shown that
thiazolidinediones are associated with decreases in BMD
and increase in fracture rates [16, 23, 24, 32, 36]. In contrast,
metformin, glucagon-like peptide-1 receptor agonists (GLP-1)
and sulfonylureas have been reported to decrease the risk for
fracture and BMD loss [23–26, 32, 36]. Studies looking at the
effect of insulin in particular have yielded conflicting results.
Three studies found that exogenous insulin increased BMD
[21, 23, 32], three studies found no effect on bone [29, 30, 36],
and three studies found that insulin decreased bone loss or
increased rate of fracture [24, 37, 38]. Barrett-Conner et al.
found that exogenous insulin therapy removes the impact of
endogenous insulin as an anabolic agent on bone.
Insulin is usually a last line of treatment for those with
T2DM. Therefore, people who initiate insulin therapy are
more likely have more comorbidities as well as a more severe
disease progression. Several studies found that advanced disease also increased the risk for fracture [21, 24–26]. One study
did not find any effect on fracture. [29].
At present, there is little known about the longitudinal effects
of insulin initiation on bone health. The purpose of the current
study was to evaluate the effect of insulin initiation on longitudinal changes in BMD, using the pharmacoepidemiology statistical new user design methodology [39] and propensity score
matching.
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or early perimenopausal, had an intact uterus, had at least one
intact ovary, were not currently taking hormone therapy or
oral contraceptives, were not pregnant or lactating, and had
≥ 1 menstrual period in the previous 3 months. After enrollment, women were seen annually. They were instructed to
bring in all medication containers, and trained interviewers
transcribed all medications onto the study form. Five of the
seven sites conducted a bone health study, with BMD as one
of its main outcomes; this involved 2365 women.
The current analysis examined whether the initiation of
insulin in subjects with DM was associated with an increased
loss of BMD at the femoral neck (FN) and spine and if insulin
increased the risk for fracture. To examine this, we compared
the annualized percent rate of change in BMD among diabetic
women who started insulin compared to non-users of insulin.
The visit before insulin initiation was considered baseline for
the user group. For those with DM who never reported insulin
use, we randomly selected a frequency-matched visit to establish a comparable baseline. This was to ensure a similar distribution of the baseline visit between the two groups. Using
propensity score matching, we created a matched cohort of
insulin users and non-users. These analyses were carried out
using propensity score-matched regression.
Study sample
Of the 2365 women in the bone cohort, 317 had DM based on
a longitudinal review of the subject’s history of [1] fasting
baseline glucose level ≥ 126 mg/dl at two or more visits, [2]
self-report of DM, or [3] hypoglycemic medications or insulin
use. We excluded women from this analysis if they were using
insulin at the time of enrollment into the SWAN study
(n = 29). Those that had no history of insulin use were frequency matched with the insulin initiators based on the calendar date of the index visit. Those who could not be matched
were excluded (n = 4). This left 284 women in the study. Once
propensity score (PS) matching was conducted, the final analytic sample consisted of 55 subjects in each group (Fig. 1).

Methods

Assessment of medication use

Study design

Medication use was assessed at each SWAN study visit.
Participants were asked about medications taken in the last
3 months, and responses were verified by visual inspection
of medication bottles. If the participant forgot to bring medication containers to the study visit, a review of medication lists
was performed. Each medication was then classified into its
generic name and assigned a code according to a computerized medication dictionary (Iowa Drug Information Service
(IDIS) Drug Vocabulary, College of Pharmacy, University of
Iowa, Iowa City, IA). Dosage information was not consistently listed and thus was not used for these analyses. Further, all

The Study of Women’s Health Across the Nation (SWAN)
began in 1996–1997 to study health changes during mid-life
in a multi-ethnic community-based cohort of 3302 women.
The overall aim of SWAN is to examine a wide variety of
health-related issues as women transition through menopause.
The full study design and procedures, including recruitment
and medication collection protocols have been described in
detail elsewhere [37]. Briefly, seven sites across the USA enrolled women between the ages of 42 and 52 if they were pre
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Parcipants in Longitudinal BMD and Med use
Dataset (N=2365)

Women with DM
(n=317)

Exclusions (N=33):
•Reported insulin use at baseline visit (n=29)
•Unable to be frequency matched to users
(n=4)

Sample aer frequency matching
(N=284)
Insulin Users (n=68)
Non-Users (n=216)

Propensity Score Matched Sample
(Primary Analyses)
Insulin Users (n=55)
Non-Users (n=55)

Fig. 1 Flow chart of subject inclusion. This figure demonstrates the
assembly of the primary analytic cohort. The primary cohort used
propensity scores to match initiators of insulin with those who never
used insulin

insulin preparations were considered equal for the purposes of
these analyses.

Bone mineral density measurements
The BMD (g/cm2) of the lumbar spine and femoral neck were
measured annually using Hologic instruments (Hologic Inc.,
Waltham, Massachusetts). Three sites used Hologic 4500A
models at baseline; two of these sites later upgraded to
Discovery models, one at follow-up visit 12 and one at
follow-up visit 13. Two sites started with 2000 models at
baseline and both of upgraded to 4500 models at follow-up
visit 8. Each site that upgraded its hardware scanned 40 volunteers on both old and new machines to develop crosscalibration regression equations, which were applied by the
SWAN Coordinating Center. A standard quality control (QC)
program was conducted in collaboration with QC centers at
Synarc Inc. (San Francisco, CA) from baseline to follow-up
visit 10 and with the USCF DXA Quality Assurance Center
(San Francisco, CA) thereafter. QC included daily phantom
measurements, quarterly review of the daily QC plots by the
QC centers with correction factors applied for drift if needed,
local site review of all scans, and review of problem scans by a
member of the SWAN Bone Committee. Short-term in vivo
measurement variability was 0.014 g/cm2 (1.4%) for the LS
and 0.016 g/cm2 (2.2%) for the FN.

Statistical analysis
After comparing the baseline characteristics between the user
and non-user groups, it was found that there was a considerable imbalance between the two. Therefore, we chose to improve the comparability of groups by using propensity score
(PS) as a method for matching women in the user group to
women in the non-user group. PS matching usually involves
the formation of pairs of treated and untreated subjects with
similar propensity scores. Greedy matching is commonly used
for the formation of these pairs. This means that for a given
treated subject, the closest untreated subject within the specified caliper distance is selected for matching to the treated
subject. Logistic regression models are mostly used and those
baseline variables that influence treatment assignment are included in the model. In this analysis, the following variables
were used to calculate the PS: age, race, BMI, smoking status,
menopausal status, baseline FN and spine BMD, and number
of comorbid conditions (anemia, hypertension, hyperlipidemia, migraine, stroke, osteoarthritis, myocardial infarction,
angina, osteoporosis, thyroid disease, any cancer). A greedy
matching caliper was set at 0.2 of the standard deviation of the
logit of the PS [40].
Descriptive statistics (mean, median, and range) of the
baseline demographic variables were calculated. Continuous
variables were analyzed using Student’s t test, or the nonparametric analog; whereas categorical variables were analyzed
using χ 2. Variables were transformed where necessary.
Standardized mean differences (SMD) were then calculated
to examine improvement in balance between the two groups.
To compare the annualized rate of change in BMD among
the insulin users and non-users, a mixed-effects regression
modeling strategy, allowing for a random intercept and slope,
was used [41]. Factors selected a priori for inclusion in the
base models included years from the baseline visit as a continuous linear covariate and several covariates known to be
possible correlates of BMD. Study site, race (Caucasian,
African American, Chinese, Japanese), and diabetes duration
were time-invariant, whereas age, BMI, medications known to
affect BMD (hormone use, thiazide diuretics, bisphosphonates),
number of comorbid conditions, fasting blood glucose (FBG),
calcium, vitamin D, physical activity, and menopausal status
were time varying. Since some antidiabetic medications have
been reported to affect BMD, concurrent use of metformin,
sulfonylureas, and thiazolidinediones were also included. A
sensitivity analysis removing those that used thiazide diuretics
at baseline was also conducted. For consistency, if a covariate
was found to be significant at one anatomical site (i.e., femoral
neck), that covariate was forced into the other site. Therefore,
all final models for each comparison group contain the same
covariates and only included the a priori variables and other
covariates with P values < 0.05. SAS version 9.3 (SAS
Institute, Inc., Cary, NC) was used for the analyses.
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A secondary analysis of BMD change over time in only the
insulin user group was carried out using a piecewise mixed
model regression. Again a random intercept and slope was
use. Since it was thought that insulin might have a cumulative
effect on bone, a longer follow-up period was examined after
initiation. Therefore, time in the model included up to 3 years
prior to insulin initiation and all data points after.

Results
The analytic sample consisted of 110 women; 49% were white
and 51% black. After PS matching, women using insulin
(n = 55) were similar in age, BMI, FN BMD, educational
attainment, smoking status, menopausal status, calcium, vitamin D, thiazide diuretic, and bisphosphonate use (Table 1)
compared to the women not using insulin (n = 55). Insulin
users had a higher FBG (187.8 mg/dl vs 144.3 mg/dl) and
were concurrently on thiazolidinediones, metformin, and sulfonylureas compared to the non-user group. Diabetes duration
for the user group was 9.1 vs. 5.7 years for the non-user group.
The mean number of BMD scans was 4.0 (STD = 2.9) per
person.
Figure 2 shows the annual percent change in BMD at the
FN spine and total hip for the PS matched sample. After
adjusting for age, BMI, race, site, menopausal status, FBG,
smoking status, diabetes duration, calcium, vitamin D, hormone, bisphosphonate, thiazide diuretic, metformin, sulfonylurea, physical activity, and thiazolidinedione use, those using
insulin had a greater decrease in BMD at the FN (− 1.1 vs
− 0.77%; p = 0.04) than those not using insulin. The annual
change at the spine and total hip was similar between the two
groups. Since thiazide diuretic use has been shown to increase
BMD, a sensitivity analysis was conducted removing women
who were using these at baseline (Fig. 3). The results were
similar to the primary analysis, with users losing 1.23% at the
FN compared to − 0.87% in the non-users (p = 0.046). Again,
there was no difference at the spine or total hip between the
two groups.
Figure 4 illustrates the results from the secondary piecewise mixed model analysis for those who initiated insulin.
After adjusting for age, race, BMI, menopausal status, and
physical activity the within women slope after insulin initiation at both the FN and the total hip are significant (FN
− 1.3%; p = 0.001, total hip − 0.75% p = 0.005). The comparison of the slopes pre- and post-insulin use at all three anatomic sites were not significant. As an exploratory analysis,
we examined the effect of insulin on fractures. There were a
total of 14 fractures among women in the analysis sample. The
most common fracture was foot (n = 6), followed by arm
above the wrist (n = 2), leg (n = 2), ankle (n = 2), patella
(n = 1), and other (n = 1) fracture. Nine of the 14 fractures
were non-traumatic. After adjusting for age, race, BMI,
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baseline FN BMD, and menopausal status, there was no difference in fracture risk (HR 1.4; 95% CI 0.43–4.3; P
value = 0.81).

Discussion
We studied a longitudinal cohort of 110 women with diabetes
who were enrolled in SWAN to determine if there was a difference in BMD loss and fracture risk between those that
initiated insulin and those who did not. Initiation of insulin
was found to be associated with greater rates of decline at the
femoral neck after adjusting for age, BMI, race, site, menopausal status, current smoking status, FBG, education, diabetes duration, hormone user, bisphosphonate, calcium, vitamin
D, physical activity, thiazide diuretic, metformin, sulfonylurea, and thiazolidinedione use. There were no differences
found in BMD loss at the spine or total hip.
There are several mechanisms that can affect bone health in
T2DM. First, hyperglycemia has been found to attenuate bone
density by reducing osteoblast function and number,
inhibiting osteoblast maturation and bone mineralization,
impairing the response to 1, 25 hydroxy vitamin D3, and
inducing glycation of various proteins and produce advanced
glycosylation end products (AGEs) [19, 23, 25, 26, 31, 32,
36]. In cortical bone, an accumulation of AGEs can affect the
rigidity of the bone but does not seem to affect bone mineralization [23]. The result seen in the FN of this study may
suggest that exogenous insulin use may be affecting bone loss
independent of FBG levels which were consistently higher in
those that initiated insulin.
Second, insulin has both a direct and indirect effect on
osteogenesis. The direct effect is mediated through insulin
and insulin-like growth factor-1 (IGF-1) receptors located on
the osteoblast [23]. The indirect effect of insulin is mediated
through the control of blood glucose levels and its effects on
the parathyroid hormone, IGF-1, and vitamin D. In animal and
clinical studies, it has been repeatedly shown that those with
type 1 DM (T1DM) the BMD of the FN is lower than those
with T2DM. This is thought to be due to a lack of insulin in
T1DM but that in T2DM it could be explained by a higher
BMI [18, 19, 23, 25, 26]. Since it is known that exogenous
insulin increases weight gain, in this study, both the insulin
and non-insulin user groups were matched on BMI at baseline.
Also, an analysis was carried out to see if there was a significant change in BMI between the two groups. We found a
small but not statistically significant difference in BMI of
0.38 (insulin starters) vs − 0.75 (non-starters) (p = 0.25).
Also, BMI which was incorporated in the models as a time
varying covariate was not found to be significant at any site.
Third, other antidiabetic agents have been found to have
both positive and negative impacts on bone health.

Osteoporos Int (2018) 29:347–354
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Table 1 Baseline characteristics
of women with type 2 diabetes
mellitus
Variable

Total N = 110

Non-insulin user N = 55

Insulin user N = 55

n

n

n

%

%

SMD

%

Age, mean (SD)

53.6

5.30

53.9

5.70

53.3

4.90

0.10

BMI, mean (SD)

35.7

6.70

35.5

6.50

35.8

7.00

0.05

Diabetes duration, mean (SD)

7.4

4.80

5.7

5.00

9.1

4.00

0.76

Femoral neck BMD, mean (SD)
Spine BMD, mean (SD),

0.92
1.2

0.15
0.16

0.91
1.1

0.15
0.16

0.93
1.2

0.14
0.16

0.16
0.27

Total hip BMD, mean (SD)
Total comorbidities, mean (SD)

1.07
2.6

0.16
1.20

1.05
2.5

0.16
1.30

1.09
2.8

0.16
1.10

0.23
0.22

Follow-up (years) mean (SD)

6.2

4.60

5.7

5.00

6.8

4.10

0.25

Fasting blood glucose (mg/dl)

166.3

73.70

144.3

61.20

187.8

79.00

0.62

Physical activity
Educational attainment
Up to high school

6.8

1.7

7.0

1.8

6.6

1.7

0.25

47

0.43

25

0.45

22

0.40

0.11

Beyond high school

63

0.57

30

0.55

33

0.60

Tobacco use
Current
Site

33

0.30

18

0.33

15

0.27

0.12

Michigan
Mass General

49
21

0.45
0.19

25
11

0.45
0.20

24
10

0.44
0.18

0.04
0.05

UC Davis
UCLA

7
7

0.06
0.06

2
3

0.04
0.05

5
4

0.09
0.07

0.23
0.08

Pittsburgh

26

0.24

14

0.25

12

0.22

0.09

54
56

0.49
0.51

28
27

0.51
0.49

26
29

0.47
0.53

0.07

Race
White
Black
Menstrual status
Pre

8

0.07

5

0.09

3

0.05

0.14

Early/late peri
Post
Unknown*
Medication use
Hormone replacement

26
63
13

0.24
0.57
0.12

13
32
5

0.24
0.58
0.09

13
31
8

0.24
0.56
0.15

0.00
0.04
0.17

11

0.10

4

0.07

7

0.13

0.18

Bisphosphonate
Thiazide diuretic
Vitamin D
Calcium
Oral hypoglycemics
Thiazolidinedione
Metformin

2
27
16
17

0.02
0.25
0.15
0.15

1
14
10
8

0.02
0.25
0.18
0.15

1
13
6
9

0.02
0.24
0.11
0.16

0.00
0.04
0.21
0.05

16
66

0.15
0.60

3
31

0.05
0.56

13
35

0.24
0.64

0.53
0.15

Sulfonlyurea

38

0.35

7

0.13

31

0.56

1.00

SMD standardized mean difference
*Unknown because of hormone therapy or surgery

For example, studies have found that metformin and sulfonylureas have positive effects on bone health. Whereas,
thiazolidinediones have a negative impact. Exogenous insulin
has remained controversial. While numerous studies have
found endogenous insulin to have an anabolic effect on bone

[18–22], Dutta found that exogenous insulin therapy removes
the impact of endogenous insulin. He also found that insulin
will inhibit C-peptide release which leads to a negative impact
on bone [37]. Newer hypoglycemic agents such as glucagontype peptide (GLP-1) agonists have been found to be
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Percent Loss BMD

Percent Loss BMD
1
FEMORAL NECK

SPINE
-0.32

-0.30

TOTAL HIP
-0.25
-0.31

0.98
0.96
0.94
0.92
0.9

-0.77

0.88

P=0.85
P=0.04

P=0.71

-1.13

No Insulin

associated with both bone loss and gain and sodium-glucose
co-transporter 2 (SGLT2) inhibitors where found to be detrimental to bone. Since these latter drugs were not introduced in
the USA at the time of data collection, we were unable to
ascertain the effects of these drugs on this study.
Disease severity, treatment modalities, and duration of diabetes have been found to increase the risk for both microvascular and macrovascular condition [1–5] as well as increase
the risk for fracture. In this study, those that initiated insulin
had a higher number of comorbid conditions (2.8 vs 2.5),
higher FBG (187.8 vs 144.3 mg/dl) and had T2DM for a
longer period of time (9.1 vs 5.1 years) all indicating an advanced disease state. To control for these potential confounding covariates, we PS matched or adjusted for these covariates
in all models.
Four prior studies examined insulin use and its effects on
BMD. The current results showing an association between

Percent Loss BMD
SPINE
-0.43

TOTAL HIP
-0.42

-0.40

-0.45

-0.87

-1.23

P=0.95

P=0.72

P=0.046
No Insulin

-3 years -2 years -1 year

Insulin 1 year
Iniaon

Femoral Neck (p=0.001)

Insulin

Fig. 2 Annualized percent of bone mineral density loss between insulin
users and non-users. All BMD models adjusted for age, BMI, race, site,
menopausal status, current smoking status, FBG, physical activity,
education, diabetes duration, hormone user, bisphosphonate, calcium,
vitamin D, thiazide diuretic, metformin, sulfonylurea, and
thiazolidinedione use

FEMORAL NECK

0.86

Insulin

Fig. 3 Annual Percent of bone mineral density loss between insulin users
and non-users after removing thiazide diuretic users at baseline. All BMD
models adjusted for age, BMI, race, site, menopausal status, current
smoking status, FBG, education, physical activity, diabetes duration,
hormone user, bisphosphonate, calcium, vitamin D, thiazide diuretic,
metformin, sulfonylurea, and thiazolidinedione use

2 year

Spine (p=0.44)

3 year

4 year

5 year

Total Hip (p=0.005)

Fig. 4 Annual percent of bone mineral density loss before and after
insulin initiation. Models adjusted for age, race, BMI, menopausal
status, and physical activity P values reflect within person change after
insulin initiation

insulin use and a decrease in BMD at the FN are consistent
with findings from a prior study by Dutta [37]. While both
studies included women of similar age (53 years old), the
SWAN database allowed us to include additional covariates
known to affect BMD, such as menopausal status, coexisting
comorbid conditions, and medications that affect BMD such
as hormone therapy, thiazide diuretics, and bisphosphonates,
and socio-economic factors. Further, our study had a median
follow-up of 5.4 years, compared to only 1 year, which further
distinguishes the results of the current analysis.
Our study has several strengths, including a well characterized cohort and a longitudinal design allowing up to 13 data
points per person. Also, we could track BMD loss from the
onset of insulin therapy in conjunction with other medications
for diabetes and medications for other conditions while
adjusting for menopausal status. The relationship between
menopausal status and BMD has been well characterized in
SWAN [42], adding to the robust nature of the current analyses. Compared to the rates of BMD loss in a previously published SWAN study whose mean BMI was 27, our rates of
bone loss are similar. Since BMI has a protective effect on
bone, we would have expected a much slower rate of decline
in this study. Thus, it supports the conclusion that insulin use
may be a major contributing factor for the accelerated bone
loss. Most prior studies have been cross-sectional, have not
adjusted for menopausal status or other bone active medications, comorbid conditions, or did not employ a new user
design. New user designs are the preferred method in
pharmacoepidemiology studies [39]. Though a new user design does not create balanced baseline comparisons, we were
able to achieve this using propensity score matching.
There are, however, limitations to the current study. As
this is an observational analysis, imbalances in subject
characteristics could explain differences in BMD; thus,
determining causation would require a RCT. Further, to
balance our groups, we sacrificed statistical power for an
improvement in the balance of subject characteristics. In
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this study, power ranged from 85 to 98% with an alpha of
0.05 for this analysis. Finding a significant results indicates sufficient power. However, whenever a statistical
analysis is performed and results interpreted, there is always a finite chance that the results are purely by chance.
This is an inherent limitation of any statistical analysis
and cannot be done away with. Another limitation could
have been that some women had type 1 DM. In an attempt
to eliminate this possibility, those women that were on
insulin at SWAN baseline were removed from the study
cohort (n = 29). Finally, since SWAN was specifically
designed for assessing women as they transition through
menopause, these results may not be generalizable to
men. Despite these limitations, to our knowledge, this is
the first longitudinal study to examine insulin use and
bone loss that was adjusted for potential confounders such
as comorbid conditions, socioeconomic status, and menopausal status while using the preferred pharmacoepidemiologic statistical new user design methodology.
In conclusion, we found that insulin use was associated
with increased bone loss at the FN but not at the spine or total
hip. These results suggest that when making treatment decisions for women with diabetes special consideration should be
given to women who are at a high risk for osteoporosis.
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